Publications by authors named "Barbara Geerinckx"
Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy.
Expert Rev Anticancer Ther
December 2023
Article Synopsis
- Patients with metastatic pancreatic cancer have a really low survival rate of only 3-5% over 5 years because there aren't many effective treatments available.
- Only a small number of patients with a specific gene mutation see better outcomes with a drug called olaparib.
- New treatment methods are being explored, focusing on improving the tumor environment and using advanced DNA testing to personalize therapies for patients.
New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.
Curr Treat Options Oncol
August 2023
One of the great challenges in digestive oncology is choosing the optimal therapy for RAS-mutated metastatic colorectal cancer (mCRC). Even though the RAS genes and accompanying pathway were identified decades ago and extensive knowledge exists on their role in carcinogenesis, it has proven challenging to translate these insights into new therapies and clinical benefit for patients. However, recently, new drugs targeting this pathway (for example, KRAS inhibitors) have shown promising results in clinical trials, as monotherapy or in combination regimens.
View Article and Find Full Text PDFHemodialysis-related portosystemic encephalopathy (HRPSE) is a clinical phenomenon where portosystemic encephalopathy (PSE) develops without liver dysfunction, usually caused by changes in the portosystemic blood flow related to hemodialysis. We describe the case of a 22-year old patient with a transjugular intrahepatic portosystemic shunt (TIPS) who developed HRPSE several months after initiation of hemodialysis. Despite initial therapy with laxatives and neomycin symptoms recurred.
View Article and Find Full Text PDF